As was demonstrated for bladder cancer, tumor cells with low KMT2C activity experienced a deficiency of DNA repair mediated by homologous recombination and suffer from endogenous DNA damage and genomic instability, and their treatment with the PARP1/2 inhibitor olaparib leads to synthetic lethality [16]. The gene discussed is PARP1; the disease is urinary bladder carcinoma.